OncLive - "Using the New Therapeutic Options in Multiple Myeloma"
With the approval of carfilzomib in July 2012 and pomalidomide in February 2013, new therapeutic options are available for the treatment of multiple myeloma (MM). At the 17th Annual International Congress on Hematologic Malignancies, Sundar Jagannath, MD, professor of Medicine and Director, Multiple Myeloma Program, The Tisch Cancer Institute at Mount Sinai Medical Center, spoke about evidence for use of these treatment options in clinical practice. Thalidomide, lenalidomide, and pomalidomide are structurally similar, but functionally they are different, both qualitatively and quantitatively, said Dr. Jagannath. Learn more